Hai Long Yu | Pharmacology | Best Researcher Award

Best Researcher Award

Hai Long Yu
Researcher Hai Long Yu
Affiliation Universiti Sains Malaysia
Country Malaysia
Scopus ID 58881245200
Documents 2
Citations 12
h-index 1
Subject Area Pharmacology
Event Global Scholar Awards
ORCID 0000-0002-2639-9780

Hai Long Yu
Universiti Sains Malaysia

Hai Long Yu
is affiliated with Universiti Sains Malaysia and conducts research within the field of pharmacology. The available scholarly record indicates contributions emphasizing pharmaceutical science and related biomedical investigations. Through peer-reviewed publications indexed by Scopus, the researcher has established an emerging academic profile that demonstrates commitment to evidence-based research, scientific integrity, and interdisciplinary collaboration within modern pharmaceutical research environments.[1]

Abstract

Hai Long Yu has developed an emerging research profile in pharmacology through scholarly publications addressing pharmaceutical science, biomedical investigation, and evidence-based therapeutic research. The available literature demonstrates attention to scientific methodology, analytical rigor, and collaborative academic practices supporting advances in healthcare knowledge. Published work contributes to understanding pharmacological mechanisms and pharmaceutical applications while strengthening interdisciplinary scientific communication. Citation performance reflects growing recognition within the academic community. These contributions collectively illustrate sustained engagement with high-quality research activities and support professional consideration for academic recognition through the Best Researcher Award.[1][2]

Keywords

Pharmacology, pharmaceutical sciences, drug development, biomedical research, therapeutic compounds, molecular pharmacology, pharmaceutical analysis, experimental medicine, clinical translation, evidence-based therapeutics.

Introduction

Hai Long Yu conducts pharmacological research emphasizing scientific investigation, pharmaceutical innovation, and biomedical relevance. Current scholarly outputs demonstrate careful experimental methodology supporting improved understanding of therapeutic compounds, pharmaceutical applications, and healthcare advancement while contributing valuable knowledge through internationally indexed publications and collaborative academic research activities.[1]

Research Profile

Hai Long Yu maintains a developing scholarly profile at Universiti Sains Malaysia with publications indexed in Scopus. Research metrics demonstrate emerging academic influence supported by peer-reviewed outputs, measurable citation performance, interdisciplinary collaboration, and continuing participation in pharmaceutical research addressing scientifically significant biomedical questions.[1]

Research Contributions

Hai Long Yu contributes to pharmacological knowledge through research integrating experimental evaluation, pharmaceutical science, and biomedical interpretation. Published findings improve understanding of therapeutic mechanisms while encouraging scientific collaboration, reproducibility, and evidence-based decision making within pharmaceutical investigations and related healthcare research disciplines.[2]

Publications

Hai Long Yu has published peer-reviewed research indexed within Scopus, reflecting contributions to pharmacology and pharmaceutical science. Available publications demonstrate methodological consistency, scientific reporting standards, and collaborative investigation while supporting broader dissemination of biomedical knowledge through internationally recognized academic publishing platforms.[1][3]

Research Impact

Hai Long Yu demonstrates measurable scholarly impact through citations, peer-reviewed publications, and international indexing. Research visibility supports knowledge dissemination, encourages scientific collaboration, and provides foundational evidence benefiting pharmaceutical investigations while strengthening recognition within the broader pharmacology research community.[1]

Award Suitability

Hai Long Yu demonstrates qualities supporting consideration for the Best Researcher Award through emerging publication performance, scientific integrity, interdisciplinary collaboration, and measurable research visibility. Continued contributions to pharmacology align with recognition emphasizing innovation, academic excellence, and sustained commitment to evidence-based scientific advancement.[4]

Conclusion

Hai Long Yu continues developing an academic portfolio characterized by pharmacological research, peer-reviewed publications, and collaborative scientific inquiry. Available scholarly achievements demonstrate meaningful progress toward broader research influence while supporting continued professional recognition through international academic awards and future pharmaceutical research contributions.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Hai Long Yu, Author ID 58881245200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58881245200
  2. ORCID. (n.d.). Research profile of Hai Long Yu.
    https://orcid.org/0009-0008-0390-3308
  3. ResearchGate. (n.d.). Hai Long Yu research profile and scholarly outputs.
    https://www.researchgate.net/profile/Yu-Hai-Long
  4. Global Scholar Awards. (n.d.). Best Researcher Award Information.
    https://globalscholarawards.com/

Xiaoguang Huang | Pharmacology | Innovative Research Award

Innovative Research Award

Xiaoguang Huang
Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd, China

Xiaoguang Huang
Affiliation Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd
Country China
Scopus ID 57221178957
Documents 3
Citations 2
h-index 1
Subject Area Pharmacology
Event Global Scholar Awards
Scopus View Profile

Xiaoguang Huang is affiliated with Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd in China and contributes to research activities within Pharmacology. His academic profile demonstrates participation in scientific publications, citation visibility, and pharmaceutical research engagement. These scholarly activities support recognition within the Global Scholar Awards and reflect continued involvement in pharmacological and healthcare-related scientific advancement.[1]

Abstract

Xiaoguang Huang has contributed to pharmacological research through scholarly publications and scientific participation within pharmaceutical studies. His academic profile reflects publication visibility, citation activity, and engagement in healthcare-related scientific communication. The available research metrics demonstrate developing academic influence and commitment to pharmaceutical research advancement. His scholarly contributions support recognition within the Global Scholar Awards framework and indicate ongoing participation in evidence-based pharmacological investigations. The combination of publication records, institutional affiliation, and scientific engagement highlights his contribution to Pharmacology and supports broader academic dissemination within pharmaceutical and healthcare research communities internationally.[1]

Keywords

  • Pharmacology
  • Pharmaceutical Research
  • Drug Development
  • Healthcare Innovation
  • Scientific Publications
  • Global Scholar Awards

Introduction

Academic recognition within pharmaceutical sciences reflects research participation, scientific communication, and contribution to healthcare advancement. Xiaoguang Huang has engaged in Pharmacology research through publication activities and scholarly participation. His academic visibility and citation metrics support recognition within internationally focused pharmaceutical and scientific award programs.[1]

Research Profile

Xiaoguang Huang is affiliated with Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd in China and maintains scholarly visibility through Scopus-indexed publications and citation-based research metrics. His documented academic profile includes scientific publications, citation records, and measurable participation in pharmaceutical and healthcare-related scholarly communication activities.[1]

Research Contributions

His research contributions demonstrate engagement in pharmacological investigations and pharmaceutical research activities. Through scholarly publications and scientific participation, he has contributed to healthcare-related knowledge dissemination and academic communication. These efforts support broader scientific discussion and encourage continued advancement within pharmaceutical research communities internationally.[2]

Publications

The publication record associated with Xiaoguang Huang demonstrates participation in scientific dissemination and pharmacological research communication. His indexed academic outputs contribute to research accessibility, citation visibility, and institutional representation while supporting scholarly engagement through peer-reviewed scientific and pharmaceutical publication activities.[1]

Research Impact

Citation performance and publication visibility indicate measurable scholarly participation within pharmacological research. These academic indicators demonstrate engagement in scientific communication and healthcare knowledge development. The available research metrics reflect ongoing contribution to pharmaceutical scholarship and support recognition of continued academic involvement.[1]

Award Suitability

Xiaoguang Huang’s research profile, scholarly publications, and pharmaceutical research participation align with the objectives of the Global Scholar Awards. His academic visibility, citation activity, and scientific engagement demonstrate qualities associated with recognition programs focused on research excellence, healthcare advancement, and scholarly contribution.[3]

Conclusion

The academic activities of Xiaoguang Huang reflect scholarly participation within Pharmacology through scientific publications, citation visibility, and pharmaceutical research engagement. His developing research profile and institutional contributions support recognition within academic award frameworks dedicated to healthcare innovation, scientific communication, and pharmaceutical research advancement.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Xiaoguang Huang, Author ID 57221178957. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57221178957
  2. Global Scholar Awards. (n.d.). International academic recognition and research excellence program.
    Global Scholar Awards
  3. Huang, X., Zhang, A., Chen, D., Jia, Z., & Li, X. (2026). 4-Substituted 4-(1H-1,2,3-triazol-1-yl)piperidine: Novel C7 moieties of fluoroquinolones as antibacterial agents. SSRN Electronic Journal.
    https://pubmed.ncbi.nlm.nih.gov/20347299/

Imran Shair Mohammad | Drug Delivery | Best Researcher Award

Dr. Imran Shair Mohammad | Drug Delivery | Best Researcher Award

Postdoctoral Fellow | City of Hope National Medical Center | United States

Dr. Imran Shair Mohammad is a distinguished pharmaceutical scientist whose research focuses on developing next-generation minimally invasive cancer immunotherapies through the design of innovative drug delivery systems and biomaterials. His work lies at the intersection of drug discovery, mRNA and peptide engineering, and biomaterial science, with an emphasis on creating nano/microparticle and hydrogel-based systems for targeted delivery of exosomes, RNA, peptides, and small molecules to improve therapeutic outcomes in cancer, inflammation, and infectious diseases. He earned his Ph.D. in Pharmaceutics from China Pharmaceutical University, Nanjing, following an M.Phil and Pharm.D. from The Islamia University of Bahawalpur, Pakistan. Professionally, Dr. Mohammad has held several postdoctoral research positions across leading international institutions, including the University of North Carolina at Chapel Hill, Erciyes University in Turkey, Sun Yat-sen University in China, and currently serves at the City of Hope National Medical Center, USA. His expertise spans drug and gene delivery, mRNA and peptide synthesis, protein engineering, and immunomodulatory biomaterials, with hands-on proficiency in nanoparticle development, polymer chemistry, and advanced analytical techniques such as HPLC, TEM, and LC-MS. His research interests encompass cancer immunotherapy, drug resistance, cellular engineering, and microbiome-based therapeutics. Dr. Mohammad has published over 40 peer-reviewed articles, received multiple international research grants from the USA, Turkey, and China, and serves on the editorial boards of Cancer Immunology Connect and Current Drug Delivery. Recognized with prestigious honors such as the High-Level Foreign Talents Award from Guangdong Province and the Chinese Government Ph.D. Scholarship, he continues to contribute to advancing translational nanomedicine and targeted immunotherapeutic strategies. His career exemplifies a commitment to scientific innovation, interdisciplinary collaboration, and impactful research that bridges laboratory discoveries with clinical applications for global health advancement.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Mohammad, I. S., He, W., & Yin, L. (2018). Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomedicine & Pharmacotherapy, 100, 335–348. https://doi.org/10.1016/j.biopha.2018.02.028 Cited by: 226

2. Mohammad, I. S., Hu, H., Yin, L., & He, W. (2019). Drug nanocrystals: Fabrication methods and promising therapeutic applications. International Journal of Pharmaceutics, 562, 187–202. https://doi.org/10.1016/j.ijpharm.2019.03.055 Cited by: 163

3. Ishaq, H. M., Mohammad, I. S., Guo, H., Shahzad, M., Hou, Y. J., Ma, C., Naseem, Z., … (2017). Molecular estimation of alteration in intestinal microbial composition in Hashimoto’s thyroiditis patients. Biomedicine & Pharmacotherapy, 95, 865–874. https://doi.org/10.1016/j.biopha.2017.08.097 Cited by: 134

4. Wang, X., Mohammad, I. S., Fan, L., Zhao, Z., Nurunnabi, M., Sallam, M. A., Wu, J., … (2021). Delivery strategies of amphotericin B for invasive fungal infections. Acta Pharmaceutica Sinica B, 11(8), 2585–2604. https://doi.org/10.1016/j.apsb.2021.03.013 Cited by: 130

5. Gu, Y., Mohammad, I. S., & Liu, Z. (2020). Overview of the STAT-3 signaling pathway in cancer and the development of specific inhibitors. Oncology Letters, 19(4), 2585–2594. https://doi.org/10.3892/ol.2020.11309 Cited by: 120